The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.
In mid-April, the 89th Annual Meeting of the German Society of Cardiology in Mannheim was the second congress highlight for CARL. Due to the well-established role of cardiological expertise in interdisciplinary ECPR programs, the CARL Academy Team had many exciting discussions about the implementation of CARL Therapy and CARL Technology in cardiac arrest centers.
The session titled “Mechanical Cardiac Short-term Support: State of the Art” discussed the current state of studies as well as prevailing questions surrounding the topic of temporary circulatory support. Jan Belohlavek, cardiologist from Prague and one of the most renowned ECPR opinion leaders worldwide, showed in his presentation “ECPR – In whom, how, where?” that extracorporeal resuscitation in the right set-up can be a second chance of survival for an adequately selected patient clientele.
“CARL will play an important role in the treatment of cardiac arrest patients in the future and already addresses the components of the therapy bundle currently discussed as necessary to perform high-quality ECPR,” says Patrick Rauh, Commercial Director of Resuscitec GmbH.